Evidence of major differences in reported adverse events between Pfizer CV-19 VX batches.

Evidence of major differences in reported adverse events between Pfizer CV-19 VX batches. In their 2023 Danish study, statistician Max Schmeling, Dr. Vibeke Manniche and Prof. Peter Riis Hansen analyzed official Danish VX and adverse-event data and identified three distinct batch-response patterns. Schmeling argued that if the risk differed depending on which batch a person received, that risk could not have been known at the time of VX — raising a serious issue for informed consent. Manniche said the patterns appeared across less serious side effects, serious side effects and deaths, and that their later analysis of Swedish data showed a similar pattern. LINK: Batch-dependent safety of the BNT162b2 mRNA CV-19 VX https://onlinelibrary.wiley.com/doi/10.1111/eci.13998 November 21, 2023 — European Parliament, Strasbourg